Evidence map›Paper›PMID 36555638›Full record

ArticleInternational journal of molecular sciences2022

Microfibril Associated Protein 5 (MFAP5) Is Related to Survival of Ovarian Cancer Patients but Not Useful as a Prognostic Biomarker.

Katarzyna Aleksandra Kujawa, Ewa Zembala-Nożynska, Joanna Patrycja Syrkis, Alexander Jorge Cortez, Jolanta Kupryjańczyk, Katarzyna Marta Lisowska

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Katarzyna Aleksandra KujawaCenter for Translational Research and Molecular Biology of Cancer, Maria Skłodowska-Curie National Research of Oncology Center, Gliwice Branch, 44-102 Gliwice, Poland.ORCID 0000-0003-3585-1553
Ewa Zembala-NożynskaTumor Pathology Department, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, 44-102 Gliwice, Poland.
Joanna Patrycja SyrkisCenter for Translational Research and Molecular Biology of Cancer, Maria Skłodowska-Curie National Research of Oncology Center, Gliwice Branch, 44-102 Gliwice, Poland.
Alexander Jorge CortezDepartment of Biostatistics and Bioinformatics, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, 44-102 Gliwice, Poland.ORCID 0000-0003-1284-2638
Jolanta KupryjańczykDepartment of Pathology and Laboratory Diagnostics, Maria Skłodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.ORCID 0000-0001-5820-0214
Katarzyna Marta LisowskaCenter for Translational Research and Molecular Biology of Cancer, Maria Skłodowska-Curie National Research of Oncology Center, Gliwice Branch, 44-102 Gliwice, Poland.ORCID 0000-0001-9786-3993

Funding

National Science Centre Poland Miniatura 3 2019/03/X/NZ5/00564
6 · The paper itself

Abstract

Ovarian cancer (OC) is usually diagnosed late due to its nonspecific symptoms and lack of reliable tools for early diagnostics and screening. OC studies concentrate on the search for new biomarkers and therapeutic targets. This study aimed to validate the

Indexed as

Contractile ProteinsOvarian NeoplasmsBiomarkers, TumorFemaleHumansIntercellular Signaling Peptides and ProteinsMicrofibrilsPrognosisRNA, MessengerBiomarkers, TumorContractile ProteinsIntercellular Signaling Peptides and ProteinsRNA, MessengercBioPortalCSIOVDBimmunohistochemistryKaplan-Meier plotterMAGP2MFAP5microfibril-associated glycoprotein 2microfibril-associated protein 5ovarian cancerprognostic markersstring

Identifiers

PMID36555638
PMCPMC9787877

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.